-
Something wrong with this record ?
Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation
P. Klener, D. Salek, R. Pytlik, H. Mocikova, K. Forsterova, P. Blahovcova, V. Campr, V. Prochazka, A. Obr, R. Jaksa, J. Kuntscherova, L. Boudová, R. Kodet, A. Janikova, M. Trneny,
Language English Country United States
Document type Clinical Trial, Letter, Research Support, Non-U.S. Gov't
Grant support
PROGRES Q28/LF1
Ministry of Education, Youth and Sports Institutional Support for Long-term Development of Research Organizations - International
PROGRES Q26/LF1
Ministry of Education, Youth and Sports Institutional Support for Long-term Development of Research Organizations - International
UNCE/MED/016
Ministry of Education, Youth and Sports Institutional Support for Long-term Development of Research Organizations - International
AZV 17-28980A
Ministry of Education, Youth and Sports Institutional Support for Long-term Development of Research Organizations - International
Charles University Center of Excellence - International
Ministry of Health of the Czech Republic - International
NV17-28980A
MZ0
CEP Register
Digital library NLK
Full text - Article
NLK
Free Medical Journals
from 1998 to 1 year ago
Wiley Free Content
from 1996 to 1 year ago
PubMed
30474171
DOI
10.1002/ajh.25362
Knihovny.cz E-resources
- MeSH
- Survival Analysis MeSH
- Transplantation, Autologous MeSH
- Progression-Free Survival MeSH
- Adult MeSH
- Remission Induction methods MeSH
- Middle Aged MeSH
- Humans MeSH
- Lymphoma, Mantle-Cell mortality therapy MeSH
- Antineoplastic Combined Chemotherapy Protocols therapeutic use MeSH
- Rituximab therapeutic use MeSH
- Aged MeSH
- Hematopoietic Stem Cell Transplantation MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Letter MeSH
- Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
1st Medical Department Charles University General Hospital Prague Czech Republic
Department of Hematology and Oncology Masaryk University Hospital Brno Czech Republic
Department of Pathology Charles University Medical Faculty Plzen Prague Czech Republic
Institute of Pathology Charles University General Hospital Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19045116
- 003
- CZ-PrNML
- 005
- 20200113081735.0
- 007
- ta
- 008
- 200109s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ajh.25362 $2 doi
- 035 __
- $a (PubMed)30474171
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Klener, Pavel $u First Medical Department, Charles University General Hospital, Prague, Czech Republic. Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 245 10
- $a Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation / $c P. Klener, D. Salek, R. Pytlik, H. Mocikova, K. Forsterova, P. Blahovcova, V. Campr, V. Prochazka, A. Obr, R. Jaksa, J. Kuntscherova, L. Boudová, R. Kodet, A. Janikova, M. Trneny,
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a transplantace hematopoetických kmenových buněk $7 D018380
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lymfom z plášťových buněk $x mortalita $x terapie $7 D020522
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a doba přežití bez progrese choroby $7 D000077982
- 650 _2
- $a indukce remise $x metody $7 D012074
- 650 _2
- $a rituximab $x terapeutické užití $7 D000069283
- 650 _2
- $a analýza přežití $7 D016019
- 650 _2
- $a autologní transplantace $7 D014182
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a dopisy $7 D016422
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Salek, David $u Department of Hematology and Oncology, Masaryk University Hospital, Brno, Czech Republic.
- 700 1_
- $a Pytlik, Robert $u First Medical Department, Charles University General Hospital, Prague, Czech Republic.
- 700 1_
- $a Mocikova, Heidi $u Department of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Forsterova, Kristina $u First Medical Department, Charles University General Hospital, Prague, Czech Republic.
- 700 1_
- $a Blahovcova, Petra $u First Medical Department, Charles University General Hospital, Prague, Czech Republic.
- 700 1_
- $a Campr, Vit $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University Hospital, Motol, Czech Republic.
- 700 1_
- $a Prochazka, Vit $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Obr, Ales $u Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic.
- 700 1_
- $a Jaksa, Radek $u Institute of Pathology, Charles University General Hospital, Prague, Czech Republic.
- 700 1_
- $a Kuntscherova, Jana $u Department of Pathology, Charles University Medical Faculty Plzen, Prague, Czech Republic.
- 700 1_
- $a Boudová, Ludmila $u Department of Pathology, Charles University Medical Faculty Plzen, Prague, Czech Republic.
- 700 1_
- $a Kodet, Roman $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University Hospital, Motol, Czech Republic.
- 700 1_
- $a Janikova, Andrea $u Department of Hematology and Oncology, Masaryk University Hospital, Brno, Czech Republic.
- 700 1_
- $a Trneny, Marek $u First Medical Department, Charles University General Hospital, Prague, Czech Republic.
- 773 0_
- $w MED00000251 $t American journal of hematology $x 1096-8652 $g Roč. 94, č. 2 (2019), s. E50-E53
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30474171 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200109 $b ABA008
- 991 __
- $a 20200113082107 $b ABA008
- 999 __
- $a ok $b bmc $g 1483385 $s 1083789
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 94 $c 2 $d E50-E53 $e 20181213 $i 1096-8652 $m American journal of hematology $n Am J Hematol $x MED00000251
- GRA __
- $a PROGRES Q28/LF1 $p Ministry of Education, Youth and Sports Institutional Support for Long-term Development of Research Organizations $2 International
- GRA __
- $a PROGRES Q26/LF1 $p Ministry of Education, Youth and Sports Institutional Support for Long-term Development of Research Organizations $2 International
- GRA __
- $a UNCE/MED/016 $p Ministry of Education, Youth and Sports Institutional Support for Long-term Development of Research Organizations $2 International
- GRA __
- $a AZV 17-28980A $p Ministry of Education, Youth and Sports Institutional Support for Long-term Development of Research Organizations $2 International
- GRA __
- $p Charles University Center of Excellence $2 International
- GRA __
- $p Ministry of Health of the Czech Republic $2 International
- GRA __
- $a NV17-28980A $p MZ0
- LZP __
- $a Pubmed-20200109
